Health ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting James Pereira Apr 6, 2023 <!-- Name:DistributionId Value:8803199 --> <!--… Read More...
Health ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the… James Pereira Sep 12, 2022 YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage… Read More...
Health ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR… James Pereira Sep 12, 2022 YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage… Read More...
Health ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial… James Pereira Aug 15, 2022 YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage… Read More...
Health ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) James Pereira May 21, 2022 YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), a late… Read More...